Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Deciphera Pharmaceuticals, LLC
Study ID
NCT06966024
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DCC-2812 — DRUG
    Administered orally

Study Details

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Key Dates

Start date
Aug 27, 2025
Status verified
May 2026
Primary completion
Feb 28, 2029
Completion
Feb 28, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: DCC-2812
    Participants will receive DCC-2812 in dose escalation manner per dosing regimen depending upon evolving pharmacokinetic (PK), pharmacodynamic, and safety data.

Primary Outcome Measure

Number of Participants with Dose-limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (28 days) ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02215
Bicky Thapa, MD
[email protected]
617-632-3000
Bicky Thapa, MD (PRINCIPAL_INVESTIGATOR)
University of MichiganAnn ArborMichigan48109
[email protected]
800-865-1125
Ulka Vaishampayan, MD (PRINCIPAL_INVESTIGATOR)
Vanderbilt- Ingram Cancer CenterNashvilleTennessee37232
Vanderbilt- Ingram Cancer Center Clinical Trials Office (CTO)
[email protected]
1-800-811-8480
Brian Rini, MD (PRINCIPAL_INVESTIGATOR)
NEXT Oncology, AustinAustinTexas78758
Clinical Trial Navigator
[email protected]
737-610-5180
Andrae Vandross, MD (PRINCIPAL_INVESTIGATOR)
NEXT Oncology, San AntonioSan AntonioTexas78229
Jordan Georg
[email protected]
210-580-9521
Ildefonso Rodriguez Rivera, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Kidney cancerBladder cancer
By specialty
OncologyUrology
By research site
Dana-Farber Cancer Institute· Boston, MAUniversity of Michigan· Ann Arbor, MIVanderbilt- Ingram Cancer Center· Nashville, TNNEXT Oncology, Austin· Austin, TXNEXT Oncology, San Antonio· San Antonio, TX

Related Studies